While loss of NHE9 function is associated with familial autism and attention deficit hyperactivity disorder, gain of NHE9 function underlies subsets of cancers such as glioblastoma and esophageal squamous cell carcinoma (23, 27, 29, 30, 31, 32, 33). Here, SLC9A9 is linked to attention deficit-hyperactivity disorder.